Current Environment: Production

Medical Services

Specialties

Programs & Services

Languages

  • English
  • French

Education

Undergraduate School

McGill University

2003, Montreal, Canada

Medical School

University of McGill

2008, Montreal, Canada

Internship

McMaster Children’s Hospital

2011, Hamilton, Canada

Residency

McMaster Children’s Hospital

2011, Canada

Fellowship

Clinical - Pediatric Gastroenterology Hepatology and Nutrition

McMaster Children’s Hospital

2012, Boston, MA, US

Fellowship

Research, Snapper Laboratory

Boston Children's Hospital

2014, Boston, MA, US

Graduate School

Scholars in Clinical Sciences Program

Harvard Medical School

2014, Boston, MA, US

Fellowship

IBD

Boston Children's Hospital

2015, Boston, US

Certifications

  • American Board of Pediatrics (Gastroenterology)
  • American Board of Pediatrics (General)

Professional History

Dr. Ouahed is a pediatric gastroenterologist involved in the clinical care of many complex patients with focus on those with Inflammatory Bowel Diseases (IBD) and immune dysregulations. Her area of expertise is in Inflammatory Bowel Disease (IBD). She attended McGill Medical School and completed her residency at McMaster Children’s Hospital in Canada. She went on to complete her fellowship in pediatric gastroenterology and nutrition, followed by an advanced fellowship in IBD at Boston Children's Hospital, where she now works as an attending physician. Dr. Ouahed is involved in several translational research projects focused on the genetics underlying early onset of IBD.

Dr. Ouahed serves as an expert for the Department of Gastroenterology for Boston Children's Hospital Precision Medicine Service. For more information about the Precision Medicine Service please visit bostonchildrens.org/precisionmed.

Publications

  1. Efficacy and Safety of Anti-Tumor Necrosis Factor Alpha in Very Early Onset Inflammatory Bowel Disease. Inflamm Bowel Dis. 2024 09 03; 30(9):1443-1453. View Abstract

  2. Breaking Down Barriers: Epithelial Contributors to Monogenic IBD Pathogenesis. Inflamm Bowel Dis. 2024 07 03; 30(7):1189-1206. View Abstract

  3. Bacterial Sphingolipids Exacerbate Colitis by Inhibiting ILC3-derived IL-22 Production. Cell Mol Gastroenterol Hepatol. 2024; 18(2):101350. View Abstract

  4. Factors Associated With Chronic Intestinal Inflammation Resembling Inflammatory Bowel Disease in Pediatric Intestinal Failure: A Matched Case-Control Study. J Pediatr Gastroenterol Nutr. 2023 04 01; 76(4):468-474. View Abstract

  5. Understanding inborn errors of immunity: A lens into the pathophysiology of monogenic inflammatory bowel disease. Front Immunol. 2022; 13:1026511. View Abstract

  6. Clinical Phenotypes and Outcomes in Monogenic Versus Non-monogenic Very Early Onset Inflammatory Bowel Disease. J Crohns Colitis. 2022 Sep 08; 16(9):1380-1396. View Abstract

  7. Mucus sialylation determines intestinal host-commensal homeostasis. Cell. 2022 03 31; 185(7):1172-1188.e28. View Abstract

  8. Pediatric Gastrointestinal Histopathology in Patients With Tetratricopeptide Repeat Domain 7A (TTC7A) Germline Mutations: A Rare Condition Leading to Multiple Intestinal Atresias, Severe Combined Immunodeficiency, and Congenital Enteropathy. Am J Surg Pathol. 2022 06 01; 46(6):846-853. View Abstract

  9. Variants in STXBP3 are Associated with Very Early Onset Inflammatory Bowel Disease, Bilateral Sensorineural Hearing Loss and Immune Dysregulation. J Crohns Colitis. 2021 Nov 08; 15(11):1908-1919. View Abstract

  10. Expanding Contributions of Monogenic Very Early Onset Inflammatory Bowel Disease. Inflamm Bowel Dis. 2021 10 20; 27(11):1870-1872. View Abstract

  11. Very Early Onset Inflammatory Bowel Disease: A Clinical Approach With a Focus on the Role of Genetics and Underlying Immune Deficiencies. Inflamm Bowel Dis. 2020 05 12; 26(6):820-842. View Abstract

  12. Risk-factors Associated With Poor Outcomes in VEO-IBD Secondary to XIAP Deficiency: A Case Report and Literature Review. J Pediatr Gastroenterol Nutr. 2019 07; 69(1):e13-e18. View Abstract

  13. Risk-factors Associated with Poor Outcomes in VEO-IBD Secondary to XIAP Deficiency: A Case Report and Literature Review. J Pediatr Gastroenterol Nutr. 2019 Feb 07. View Abstract

  14. Mucosal Gene Expression in Pediatric and Adult Patients With Ulcerative Colitis Permits Modeling of Ideal Biopsy Collection Strategy for Transcriptomic Analysis. Inflamm Bowel Dis. 2018 11 29; 24(12):2565-2578. View Abstract

  15. An integrated clinical program and crowdsourcing strategy for genomic sequencing and Mendelian disease gene discovery. NPJ Genom Med. 2018; 3:21. View Abstract

  16. Molecular Comparison of Adult and Pediatric Ulcerative Colitis Indicates Broad Similarity of Molecular Pathways in Disease Tissue. J Pediatr Gastroenterol Nutr. 2018 07; 67(1):45-52. View Abstract

  17. Genetic and Structural Analysis of a SKIV2L Mutation Causing Tricho-hepato-enteric Syndrome. Dig Dis Sci. 2018 05; 63(5):1192-1199. View Abstract

  18. Fatal Central Nervous System Disease Following First Infliximab Infusion in a Child With Inflammatory Bowel Disease. Pediatr Neurol. 2016 Apr; 57:91-4. View Abstract

  19. Fatal autoimmunity in mice reconstituted with human hematopoietic stem cells encoding defective FOXP3. Blood. 2015 Jun 18; 125(25):3886-95. View Abstract

  20. The diagnostic approach to monogenic very early onset inflammatory bowel disease. Gastroenterology. 2014 Nov; 147(5):990-1007.e3. View Abstract

  21. Interleukin 10 receptor signaling: master regulator of intestinal mucosal homeostasis in mice and humans. Adv Immunol. 2014; 122:177-210. View Abstract

  22. Role of wireless capsule endoscopy in reclassifying inflammatory bowel disease in children. J Pediatr (Rio J). 2013 Mar-Apr; 89(2):204-9. View Abstract

  23. Abdominal compartment syndrome secondary to chronic constipation. Case Rep Pediatr. 2011; 2011:562730. View Abstract

  24. Case 2: Weight loss despite tube feeding. Paediatr Child Health. 2011 Jan; 16(1):9-10. View Abstract

  25. Cryptogenic organizing pneumonia after rituximab therapy for presumed post-kidney transplant lymphoproliferative disease. Pediatr Nephrol. 2010 Jun; 25(6):1163-7. View Abstract

  26. Rituximab treatment of collapsing C1q glomerulopathy: clinical and histopathological evolution. Pediatr Nephrol. 2008 Aug; 23(8):1355-61. View Abstract
BESbswy